There is every reason to argue that the efficacy observed for compounds 1 and 2 in vivo incorporates a similar role for the host immune response as seen for other schistosomicidal agents
In 2014, the FDA approved Saxenda (a liraglutide), a daily injection that curbs craving in the brain and delays the stomach from emptying to make patients feel full for longer, specifically for weight loss
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)are FDA-approved medications for type 2 diabetes and chronic weight management
Answer: The most common side effects in retatrutide trials were mild to moderate digestive effects, including nausea, constipation, vomiting, and diarrhea, consistent with the GLP-1 class
This was not based on a formal power calculation but was within the standard range of participants in pharmacokinetic studies of people with renal impairment [13]
Disclaimer: Results may vary and treatment must be medically necessary